Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning

Hematological Oncology

Volumn 29, Issue 4, 2011, Pages 202-210

  Hamadani, Mehdi ^a   Craig, Michael ^a   Phillips, Gary S ^b   Abraham, Jame ^a   Tse, William ^a   Cumpston, Aaron ^a   Gibson, Laura ^a   Remick, Scot C ^a   Bunner, Pamela ^a   Leadmon, Sonia ^a   Elder, Patrick ^c   Hofmeister, Craig ^c   Penza, Sam ^c   Efebera, Yvonne ^c   Andritsos, Leslie ^c   Garzon, Ramiro ^c   Benson, Don M ^c   Blum, William ^c   Devine, Steven M ^c  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Allogeneic stem cell transplantation; Busulfan; Busulfan dose; Fludarabine; Graft versus host disease; Thymoglobulin

Indexed keywords

ACICLOVIR; BUSULFAN; COTRIMOXAZOLE; DAPSONE; FLUCONAZOLE; FLUDARABINE; HLA ANTIGEN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POSACONAZOLE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VALACICLOVIR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; BACTEREMIA; BACTERIAL INFECTION; CANCER INCIDENCE; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CANDIDIASIS; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; DONOR LYMPHOCYTE INFUSION; ENGRAFTMENT SYNDROME; FEMALE; GRAFT VERSUS HOST REACTION; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HEMATOLOGIC MALIGNANCY; HEMORRHAGIC CYSTITIS; HERPES SIMPLEX; HERPES ZOSTER; HODGKIN DISEASE; HUMAN; INFECTION PREVENTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; REDUCED TOXICITY CONDITIONING; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; URINARY TRACT INFECTION;

ADULT; AGED; BUSULFAN; CHIMERISM; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; OPPORTUNISTIC INFECTIONS; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE; YOUNG ADULT;

EID: 80052987567     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.985     Document Type: Article

References (31)

1. Copelan EA. Hematopoietic stem-cell transplantation.N Engl J Med 2006;354(17):1813-1826.
2. Hamadani M, Awan FT, Copelan EA. Hematopoietic stem cell transplantation in adults with acute myeloid leukemia. Biol Blood Marrow Transplant 2008;14(5):556-567.
3. Ringden O, Horowitz MM, Gale RP, et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA 1993;270(1):57-60.
4. Klingemann HG, Storb R, Fefer A, et al. Bone marrow transplantation in patients aged 45 years and older. Blood 1986;67(3):770-776.
5. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009;15(12):1628-1633.
6. Rezvani AR, Storer B, Maris M, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.J Clin Oncol 2008;26(2):211-217.
7. Rezvani AR, Norasetthada L, Gooley T, et al. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 2008;143(3):395-403.
8. Gyurkocza B, Storb R, Storer BE, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.J Clin Oncol 2010;28(17):2859-2867.
9. Kohrt HE, Turnbull BB, Heydari K, et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 2009;114(5):1099-1109.
10. de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004;104(3):857-864.
11. Russell JA, Turner AR, Larratt L, et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant 2007;13(3):299-306.
12. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91(3):756-763.
13. Mohty M, Jacot W, Faucher C, et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003;17(11):2168-2177.
14. Hamadani M, Blum W, Phillips G, et al. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2009;15(11):1422-1430.
15. Corradini P, Dodero A, Zallio F, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.J Clin Oncol 2004;22(11):2172-2176.
16. Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005;105(4):1810-1814.
17. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106(8):2912-2919.
18. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004;104(7):1923-1930.
19. Przepiorka D, Ippoliti C, Khouri I, et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 1996;88(11):4383-4389.
20. Przepiorka D, Weisdorf D, Martin P, et al.1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15(6):825-828.
21. Farmer ER. The histopathology of graft-versus-host disease. Adv Dermatol 1986;1173-1188.
22. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69(2):204-217.
23. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991;28(3):250-259.
24. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18(6):695-706.
25. Mohty M, Bay JO, Faucher C, et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003;102(2):470-476.
26. Fine JP, Gray RJ.A proportional hazards model for the subdistribution of a competing risk.J Am Stat Assoc 1999;94(446):496-509.
27. Shimoni A, Hardan I, Shem-Tov N, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006;20(2):322-328.
28. Hari P, Carreras J, Zhang MJ, et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008;14(2):236-245.
29. Cahu X, Mohty M, Faucher C, et al. Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens. Bone Marrow Transplant 2008;42(10):689-691.
30. Geddes M, Kangarloo SB, Naveed F, et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008;14(2):220-228.
31. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001;98(10):2942-2947.